Acepodia, Inc. operates as a clinical-stage biotechnology company and it develops cell therapies to treat cancer. It designed enhanced cell therapy approaches by applying Antibody-Cell Conjugation (ACC), ?d2 T2, and oNK Cells technology. The company was founded by Patrick Yuhmin Yang and Hsiao Sonny on February 15, 2017 and is headquartered in New Taipei, Taiwan.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company